• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清 microRNA 水平作为乙型肝炎病毒相关肝纤维化早期诊断的无创性诊断生物标志物。

Serum MicroRNA Levels as a Noninvasive Diagnostic Biomarker for the Early Diagnosis of Hepatitis B Virus-Related Liver Fibrosis.

机构信息

Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.

出版信息

Gut Liver. 2017 Nov 15;11(6):860-869. doi: 10.5009/gnl16560.

DOI:10.5009/gnl16560
PMID:28750488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5669603/
Abstract

BACKGROUND/AIMS: To investigate the role of selected serum microRNA (miRNA) levels as potential noninvasive biomarkers for differentiating S0-S2 (early fibrosis) from S3-S4 (late fibrosis) in patients with a chronic hepatitis B virus (HBV) infection.

METHODS

One hundred twenty-three treatment-naive patients with a chronic HBV infection who underwent a liver biopsy were enrolled in this study. The levels of selected miRNAs were measured using a real-time quantitative polymerase chain reaction assay. A logistic regression analysis was performed to assess factors associated with fibrosis progression. Receiver operating characteristic (ROC) curve and discriminant analyses validated these the ability of these predicted variables to discriminate S0-S2 from S3-S4.

RESULTS

Serum miR-29, miR-143, miR-223, miR-21, and miR-374 levels were significantly downregulated as fibrosis progressed from S0-S2 to S3-S4 (p<0.05), but not miR-16. The multivariate logistic regression analysis identified a panel of three miRNAs and platelets that were associated with a high diagnostic accuracy in discriminating S0-S2 from S3-S4, with an area under the curve of 0.936.

CONCLUSIONS

The levels of the studied miRNAs, with the exception of miR-16, varied with fibrosis progression. A panel was identified that was capable of discriminating S0-S2 from S3-S4, indicating that serum miRNA levels could serve as a potential noninvasive biomarker of fibrosis progression.

摘要

背景/目的:探讨特定血清 microRNA(miRNA)水平作为慢性乙型肝炎病毒(HBV)感染患者区分 S0-S2(早期纤维化)与 S3-S4(晚期纤维化)的潜在非侵入性生物标志物的作用。

方法

本研究纳入了 123 例未经治疗的慢性 HBV 感染患者,他们接受了肝活检。使用实时定量聚合酶链反应(PCR)检测选定 miRNA 的水平。进行逻辑回归分析以评估与纤维化进展相关的因素。接收者操作特征(ROC)曲线和判别分析验证了这些预测变量区分 S0-S2 与 S3-S4 的能力。

结果

血清 miR-29、miR-143、miR-223、miR-21 和 miR-374 水平随着纤维化从 S0-S2 进展到 S3-S4 而显著下调(p<0.05),但 miR-16 除外。多变量逻辑回归分析确定了一组三个 miRNA 和血小板与区分 S0-S2 与 S3-S4 的高诊断准确性相关,曲线下面积为 0.936。

结论

除 miR-16 外,研究 miRNA 的水平随纤维化进展而变化。确定了一组能够区分 S0-S2 与 S3-S4 的 miRNA,表明血清 miRNA 水平可以作为纤维化进展的潜在非侵入性生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f4/5669603/bb9d89514232/gnl-11-860f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f4/5669603/507b0e329d03/gnl-11-860f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f4/5669603/016cbe56b375/gnl-11-860f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f4/5669603/fe1c1b0485a5/gnl-11-860f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f4/5669603/bb9d89514232/gnl-11-860f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f4/5669603/507b0e329d03/gnl-11-860f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f4/5669603/016cbe56b375/gnl-11-860f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f4/5669603/fe1c1b0485a5/gnl-11-860f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f4/5669603/bb9d89514232/gnl-11-860f4.jpg

相似文献

1
Serum MicroRNA Levels as a Noninvasive Diagnostic Biomarker for the Early Diagnosis of Hepatitis B Virus-Related Liver Fibrosis.血清 microRNA 水平作为乙型肝炎病毒相关肝纤维化早期诊断的无创性诊断生物标志物。
Gut Liver. 2017 Nov 15;11(6):860-869. doi: 10.5009/gnl16560.
2
Serum microRNA-29 levels correlate with disease progression in patients with chronic hepatitis B virus infection.血清微小RNA-29水平与慢性乙型肝炎病毒感染患者的疾病进展相关。
J Dig Dis. 2014 Nov;15(11):614-21. doi: 10.1111/1751-2980.12185.
3
Analysis of the differential expression of circulating microRNAs during the progression of hepatic fibrosis in patients with chronic hepatitis B virus infection.慢性乙型肝炎病毒感染患者肝纤维化进展过程中循环微RNA差异表达分析
Mol Med Rep. 2015 Oct;12(4):5647-54. doi: 10.3892/mmr.2015.4221. Epub 2015 Aug 12.
4
Serum miR-17 levels in patients with hepatitis B virus induced liver fibrosis.乙型肝炎病毒诱导的肝纤维化患者血清 miR-17 水平。
Eur Rev Med Pharmacol Sci. 2020 Jun;24(11):6245-6251. doi: 10.26355/eurrev_202006_21522.
5
Serum N-glycan markers for diagnosing liver fibrosis induced by hepatitis B virus.血清 N-糖基化标志物用于诊断乙型肝炎病毒引起的肝纤维化。
World J Gastroenterol. 2020 Mar 14;26(10):1067-1079. doi: 10.3748/wjg.v26.i10.1067.
6
[A noninvasive model to predict histological liver cirrhosis in patients with chronic hepatitis B].[一种预测慢性乙型肝炎患者组织学肝硬化的非侵入性模型]
Zhonghua Gan Zang Bing Za Zhi. 2009 Jan;17(1):28-32.
7
Circulating microRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients.循环 microRNAs 作为慢性丙型肝炎(基因型 4)埃及患者肝病进展的预测生物标志物。
J Med Virol. 2019 Jan;91(1):93-101. doi: 10.1002/jmv.25294. Epub 2018 Sep 24.
8
Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B.血小板比容可作为预测慢性乙型肝炎肝纤维化的潜在指标。
J Viral Hepat. 2020 Jun;27(6):602-609. doi: 10.1111/jvh.13264. Epub 2020 Feb 8.
9
Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening.血清 miR-18a:乙型肝炎病毒相关肝细胞癌筛查的潜在标志物。
Dig Dis Sci. 2012 Nov;57(11):2910-6. doi: 10.1007/s10620-012-2317-y. Epub 2012 Aug 5.
10
Serum HBV RNA levels predict significant liver fibrosis in patients with chronic HBV infection.血清 HBV RNA 水平可预测慢性 HBV 感染患者的显著肝纤维化。
Discov Med. 2020 Mar-Apr;29(157):119-128.

引用本文的文献

1
The interactive role of microRNA and other non-coding RNA in hepatitis B (HBV) associated fibrogenesis.微小RNA及其他非编码RNA在乙型肝炎病毒(HBV)相关肝纤维化形成中的交互作用
Funct Integr Genomics. 2025 Jan 23;25(1):24. doi: 10.1007/s10142-024-01519-4.
2
Extracellular Vesicles in Viral Liver Diseases.细胞外囊泡在病毒性肝病中的作用。
Viruses. 2024 Nov 17;16(11):1785. doi: 10.3390/v16111785.
3
Serum microRNA 143 and 223 Gene Expression Profiles as Potential Biomarkers in Individuals with Hepatitis and COVID-19.血清 microRNA143 和 223 基因表达谱作为肝炎和 COVID-19 个体的潜在生物标志物。

本文引用的文献

1
MicroRNAs in liver fibrosis: Focusing on the interaction with hedgehog signaling.肝脏纤维化中的微小RNA:聚焦于与刺猬信号通路的相互作用
World J Gastroenterol. 2016 Aug 7;22(29):6652-62. doi: 10.3748/wjg.v22.i29.6652.
2
The Role of MicroRNA in Pathogenesis and as Markers of HCV Chronic Infection.微小RNA在丙型肝炎病毒慢性感染的发病机制及作为标志物中的作用
Curr Drug Targets. 2017;18(7):756-765. doi: 10.2174/1389450117666160401125213.
3
Circulating miRNAs as Predictor Markers for Activation of Hepatic Stellate Cells and Progression of HCV-Induced Liver Fibrosis.
Viruses. 2024 Nov 4;16(11):1734. doi: 10.3390/v16111734.
4
miRNA-221: A Potential Biomarker of Progressive Liver Injury in Chronic Liver Disease (CLD) due to Hepatitis B Virus (HBV) and Nonalcoholic Fatty Liver Disease (NAFLD).微小RNA-221:慢性乙型肝炎病毒(HBV)和非酒精性脂肪性肝病(NAFLD)所致慢性肝病(CLD)中进行性肝损伤的潜在生物标志物。
Int J Hepatol. 2024 Aug 16;2024:4221368. doi: 10.1155/2024/4221368. eCollection 2024.
5
MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.血清来源的细胞外囊泡中的 microRNA-223-3p 水平可预测直接作用抗病毒药物清除丙型肝炎病毒后基于 M2BPGi 的肝纤维化消退。
J Gastroenterol. 2024 Aug;59(8):719-731. doi: 10.1007/s00535-024-02115-w. Epub 2024 May 13.
6
Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients.乙肝患者肝纤维化的非侵入性评估
J Clin Med. 2024 Feb 12;13(4):1046. doi: 10.3390/jcm13041046.
7
Serum non-coding RNAs for diagnosis and stage of liver fibrosis.血清非编码 RNA 用于诊断和肝纤维化分期。
J Clin Lab Anal. 2022 Oct;36(10):e24658. doi: 10.1002/jcla.24658. Epub 2022 Aug 21.
8
Identification of Liver and Plasma microRNAs in Chronic Hepatitis B Virus infection.鉴定慢性乙型肝炎病毒感染中的肝和血浆 microRNAs。
Front Cell Infect Microbiol. 2022 Jun 2;12:790964. doi: 10.3389/fcimb.2022.790964. eCollection 2022.
9
Role of Exosomes in Chronic Liver Disease Development and Their Potential Clinical Applications.外泌体在慢性肝病发展中的作用及其潜在的临床应用。
J Immunol Res. 2022 May 6;2022:1695802. doi: 10.1155/2022/1695802. eCollection 2022.
10
MiR-223 as a Regulator and Therapeutic Target in Liver Diseases.miR-223 在肝脏疾病中的调控作用及治疗靶点
Front Immunol. 2022 Mar 16;13:860661. doi: 10.3389/fimmu.2022.860661. eCollection 2022.
循环微小RNA作为肝星状细胞激活和丙型肝炎病毒诱导肝纤维化进展的预测标志物
Electron Physician. 2016 Jan 15;8(1):1804-10. doi: 10.19082/1804. eCollection 2016 Jan.
4
Circulating miR-21 and miR-29a as Markers of Disease Severity and Etiology in Cholestatic Pediatric Liver Disease.循环miR-21和miR-29a作为小儿胆汁淤积性肝病疾病严重程度和病因的标志物
J Clin Med. 2016 Feb 25;5(3):28. doi: 10.3390/jcm5030028.
5
MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma.微小 RNA 作为肝脏疾病和肝细胞癌的生物标志物。
Int J Mol Sci. 2016 Feb 24;17(3):280. doi: 10.3390/ijms17030280.
6
miR-21 promotes fibrosis in an acute cardiac allograft transplantation model.miR-21 促进急性心脏移植移植模型中的纤维化。
Cardiovasc Res. 2016 May 15;110(2):215-26. doi: 10.1093/cvr/cvw030. Epub 2016 Feb 9.
7
MicroRNAs in fibrosis: opportunities and challenges.纤维化中的微小RNA:机遇与挑战
Arthritis Res Ther. 2016 Jan 13;18:11. doi: 10.1186/s13075-016-0929-x.
8
MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis.作为区分乙型肝炎病毒感染所致肝炎和肝硬化的疾病生物标志物的微小RNA检测板
Sci Rep. 2015 Oct 12;5:15026. doi: 10.1038/srep15026.
9
MicroRNA21 promotes interstitial fibrosis via targeting DDAH1: a potential role in renal fibrosis.微小RNA21通过靶向二甲基精氨酸二甲胺水解酶1促进间质纤维化:在肾纤维化中的潜在作用
Mol Cell Biochem. 2016 Jan;411(1-2):181-9. doi: 10.1007/s11010-015-2580-2. Epub 2015 Oct 12.
10
miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7.微小RNA-21通过靶向磷酸酶和张力蛋白同源物(PTEN)及SMAD7促进糖尿病肾病中的肾纤维化。
Clin Sci (Lond). 2015 Dec;129(12):1237-49. doi: 10.1042/CS20150427. Epub 2015 Sep 28.